|Articles|November 14, 2017
CRF Health’s TrialMax Touch® Selected for Pediatric Rare Disease Phase II Study
Advertisement
CRF Health has been selected by a specialty pharmaceutical company for its latest pediatric rare disease Phase II study. CRF Health's TrialMax Touch® handheld device alone with other solutions will be utilized to collect quality of life readings and alleviate the burden of data entry for caregivers.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
3
SCOPE X: What Real-Time Patient Data Is Doing to ClinOps Efficiency
4
SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment
5